Erik Goluboff, MD, MBA, Tyra Biosciences, Inc.

Affiliations:

Tyra Biosciences, Inc.

Carlsbad, CA, USA

Articles by Erik Goluboff, MD, MBA, Tyra Biosciences, Inc.

Oral Selective FGFR3 Inhibition in Urothelial Carcinoma: Opportunities in Intermediate Risk Non-Muscle Invasive Bladder Cancer and Low Grade Upper Tract Urothelial Carcinoma

ByErik Goluboff, MD, MBA, Tyra Biosciences, Inc.

March 30th 2026

Latest Updated Articles

Trending on Urology Times

What the Efficacy Data from KEYNOTE-B15/EV-304 Revealed

FDA reports increased demand, supply efforts for estradiol transdermal patches

Prostate Cancer Awareness Month: Prostate cancer screening in 2026

Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD

NeoBLAST trial tests active surveillance after complete response in MIBC